CCCC
C4 Therapeutics, Inc.
$4.35
+0.21 (+5.07%)
At close · Jul 7
Market Cap
$480.97M
Shares
110,567,222
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$35.95M
+1%
FY2025
Net Income
-$104.99M
+0.3%
FY2025
Operating Margin
-320.53%
+15.6pp
FY2025
Diluted EPS
-$1.27
+16.4%
FY2025
Operating Cash Flow
-$98.69M
-51.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $34.86M | $35.95M | $35.58M | $20.76M | $31.1M | $45.79M | — | — | |
| $101.77M | $104.24M | $110.64M | $117.71M | $117.84M | $94.67M | $78.44M | $48.06M | |
| $36.2M | $36.2M | $42.12M | $42.08M | $42.79M | $33.25M | $15.2M | $8.77M | |
| — | $1.96M | $1.82M | $1.88M | $1.68M | $1.49M | $1.62M | $1.6M | |
| — | $0 | $2.44M | $2.4M | — | — | — | — | |
| $148.7M | $151.17M | $155.2M | $159.79M | $160.63M | $127.92M | $93.64M | $56.83M | |
| -$113.84M | -$115.22M | -$119.61M | -$139.03M | -$129.53M | -$82.13M | -$60.45M | -$35.45M | |
| — | -320.53% | -336.15% | -669.84% | -416.56% | -179.39% | — | — | |
| — | -$113.26M | -$117.8M | -$137.15M | -$127.86M | -$80.64M | -$58.83M | -$33.86M | |
| $10.16M | $10.35M | $14.43M | $7.82M | $1.36M | -$1.76M | -$6.51M | $2.16M | |
| — | -$104.87M | -$105.19M | -$131.21M | -$128.18M | -$83.89M | -$66.96M | -$33.3M | |
| — | $121K | $131K | $1.28M | $0 | $0 | -$626K | $804K | |
| -$103.8M | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M | -$66.34M | -$34.1M | |
| — | -292.08% | -295.96% | -638.34% | -412.19% | -183.23% | — | — | |
| — | — | — | — | — | -$83.89M | -$66.34M | -$42.57M | |
| -$104.17M | -$105M | -$105.14M | -$128.48M | -$131.54M | -$84.68M | -$66.32M | -$34.1M | |
| USD/shares | — | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | -$31.03 |
| USD/shares | — | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | — | — |
| shares | — | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M | 11.37M | 1.37M |
| shares | — | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M | 11.37M | 1.37M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $821K in buybacks.